John Rothrock, MD
Neurology · Fairfax, VANPI 1174577449
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $172,763 of the $224,931 with a category attached, or 76.8%. 14 manufacturers reported payments, led by AbbVie at 52.6% of the total. Reporting peaked in 2021 at $47,087 and has fallen 59.3% since, to $19,151 in 2025. Among neurology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 372 payments — averaging $604.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$118K
- Lundbeck LLC$38K
- Amgen$30K
- Impel Pharmaceuticals Inc.$16K
- Lilly USA, LLC$8K
- Biohaven Pharmaceuticals, Inc.$5K
- plus $9K from 8 others
Across 94 payments — averaging $2969.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$180K
- Ipsen Innovation$55K
- H. Lundbeck A S$28K
- Amgen$9K
- Teva Pharmaceuticals USA, Inc.$7K
What the payments were for
- Consulting fees$36,32816%
- Speaking & faculty fees$172,76377%
- Travel & lodging$8,3284%
- Food & beverage$7,4403%
- Education$720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 232 | $118,322 |
| Lundbeck LLC | 28 | $38,180 |
| Amgen | 26 | $30,124 |
| Impel Pharmaceuticals Inc. | 11 | $15,665 |
| Lilly USA, LLC | 11 | $8,309 |
| Biohaven Pharmaceuticals, Inc. | 7 | $5,226 |
| Pfizer | 6 | $3,638 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $3,618 |
| Supernus Pharmaceuticals, Inc. | 40 | $787 |
| Biodelivery Sciences International, Inc. | 1 | $500 |
| Tonix Medicines, Inc. | 1 | $500 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Boston Scientific | 1 | $20 |
| Promius Pharma LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$66,464
- VYEPTI$37,915
- BOTOX$35,388
- QULIPTA$35,276
- AIMOVIG$25,741
- Trudhesa$15,448
- NURTEC ODT$12,233
- ZEMBRACE SYMTOUCH$500
- ZAVZPRET$249
How this compares
$224,931 in reported general payments places this provider in the 95th percentile of 474 neurology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 53 | $103,430 |
| QuliptaAtogepant | 34 | $54,275 |
| UbrelvyUbrogepant | 15 | $20,360 |
| MounjaroTirzepatide | 11 | $12,898 |
| Sumatriptan Succinate | 61 | $4,575 |
| Levetiracetam | 12 | $892 |
| RizatriptanRizatriptan Benzoate | 30 | $700 |
| Memantine Hcl | 23 | $552 |
| Donepezil Hcl | 72 | $453 |
| Levetiracetam ErLevetiracetam | 15 | $402 |
| Naproxen Sodium | 16 | $401 |
| Atorvastatin Calcium | 15 | $400 |
| Celecoxib | 26 | $380 |
| Citalopram HbrCitalopram Hydrobromide | 29 | $258 |
| Gabapentin | 22 | $218 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $3,638 | $103,43053 claims |
| AbbVieQulipta, Ubrelvy | $118,322 | $74,63649 claims |
| Lilly USA, LLCMounjaro | $8,309 | $12,89811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 474 neurology providers in Virginia.
Other neurology in Fairfax
- Rahul DaveFairfax$540K
- James SimsarianFairfax$173K
- Laura CinskiFairfax$122K
- Abigail LawlerFairfax$107K
- Amy StoneFairfax$70K
- Ramsey FalconerAlexandria$2M
- Robert ShinCharlottesville$1.7M
- Heidi CraytonVienna$1.5M
- Mark LandrioWinchester$631K
- Catherine HamRichmond$603K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.